title: Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?
authors.forename: J
authors.initials: J
authors.lastname: Peters
authors.forename: R
authors.initials: R
authors.lastname: Luddington
authors.forename: K
authors.initials: K
authors.lastname: Brown
authors.forename: C
authors.initials: C
authors.lastname: Baglin
authors.forename: T
authors.initials: T
authors.lastname: Baglin
mesh_terms: D000409:Alanine / Q000235:genetics; D000925:Anticoagulants / Q000627:therapeutic use*; D005164:Factor IX / Q000235:genetics*; D005820:Genetic Testing; D006801:Humans; D009154:Mutation; D011498:Protein Precursors / Q000235:genetics*
chemical_list: D000925:Anticoagulants; D011498:Protein Precursors; C049838:factor IX Cambridge; D005164:Factor IX; D000409:Alanine